Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Last updated: 2026-10-05 05:51:09 ET
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE